The estimated Net Worth of Street Capital Master Fund,... is at least $23.8 Миллион dollars as of 5 October 2018. Street Fund owns over 2,000,000 units of Zevra Therapeutics Inc stock worth over $23,797,260 and over the last 7 years Street sold KMPH stock worth over $0.
Sign up
Street Fund KMPH stock SEC Form 4 insiders trading
Street has made over 3 trades of the Zevra Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Street bought 2,000,000 units of KMPH stock worth $6,000,000 on 5 October 2018.
The largest trade Street's ever made was buying 2,000,000 units of Zevra Therapeutics Inc stock on 5 October 2018 worth over $6,000,000. On average, Street trades about 876,724 units every 129 days since 2017. As of 5 October 2018 Street still owns at least 4,095,914 units of Zevra Therapeutics Inc stock.
You can see the complete history of Street Fund stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Zevra Therapeutics Inc
Over the last 10 years, insiders at Zevra Therapeutics Inc have traded over $0 worth of Zevra Therapeutics Inc stock and bought 3,083,371 units worth $9,282,809 . The most active insiders traders include Street Capital Master Fund,..., David S Tierney и Travis C Mickle. On average, Zevra Therapeutics Inc executives and independent directors trade stock every 39 days with the average trade being worth of $246,727. The most recent stock trade was executed by R. La Duane Clifton on 13 January 2023, trading 635 units of KMPH stock currently worth $3,689.
What does Zevra Therapeutics Inc do?
KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LAT™ technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm's prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder. KemPharm's co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration/effect profiles. In addition, KemPharm has received FDA approval for APADAZ®, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.
What does Zevra Therapeutics Inc's logo look like?
Complete history of Street Fund stock trades at Zevra Therapeutics Inc
Zevra Therapeutics Inc executives and stock owners
Zevra Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Travis Mickle,
Chairman of the Board, President, Chief Executive Officer -
Dr. Travis C. Mickle Ph.D.,
Co-Founder, Pres, CEO & Director -
Sven Guenther,
Executive Vice President - Research and Development -
R. LaDuane Clifton,
Chief Financial Officer, Treasurer, Secretary -
Dr. Travis C. Mickle,
Co-Founder, Chairman, Pres & CEO -
Dr. Sven Guenther,
Exec. VP of R&D -
R. LaDuane Clifton CPA,
CFO, Sec. & Treasurer -
Richard W. Pascoe,
Exec. Chairman -
Jason Rando,
IR Contact Officer -
David Tierney,
Independent Director -
Joseph Saluri,
Independent Director -
Matthew Plooster,
Independent Director -
Richard Pascoe,
Lead Independent Director -
Timothy Sangiovanni,
Vice President, Corporate Controller -
Timothy J. Sangiovanni CPA,
VP & Corp. Controller -
Dr. Andrew Barrett,
VP of Scientific Affairs -
Christal M. M. Mickle,
Co-Founder and VP of Operations & Product Devel. -
Tracy M Woody,
Chief Commercial Officer -
Danny L Thompson,
Director -
Gordon K Johnson,
Chief Business Officer -
Daniel L Cohen,
EVP, Govt. & Public Relations -
Christal M M Mickle,
Chief Product Dev. Officer -
Joshua Schafer,
CCO & EVP, Bus. Development -
Samuel J Braun,
10% owner -
Tamara A Favorito,
Director